Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
BENEFICIAL EFFECT OF TREATMENT WITH A MONOCLONAL ANTITUMOR NECROSIS FACTOR-ALPHA ANTIBODY ON MARKERS OF COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH ACTIVE CROHNS-DISEASE
Autore:
HOMMES DW; VANDULLEMEN HM; LEVI M; VANDERENDE A; WOODY J; TYTGAT GNJ; VANDEVENTER SJH;
Indirizzi:
UNIV AMSTERDAM,ACAD MED CTR F4,CTR HEMOST THROMB ATHEROSCLER & INFLAMM RES,MEIBERGDREEF 9 NL-1105 AZ AMSTERDAM NETHERLANDS UNIV AMSTERDAM,ACAD MED CTR F4,CTR HEMOST THROMB ATHEROSCLER & INFLAMM RES NL-1105 AZ AMSTERDAM NETHERLANDS UNIV AMSTERDAM,ACAD MED CTR,DEPT GASTROENTEROL NL-1105 AZ AMSTERDAM NETHERLANDS UNIV AMSTERDAM,ACAD MED CTR,EXPT MED LAB NL-1105 AZ AMSTERDAM NETHERLANDS CENTOCOR INC MALVERN PA 19355
Titolo Testata:
Haemostasis
fascicolo: 6, volume: 27, anno: 1997,
pagine: 269 - 277
SICI:
0301-0147(1997)27:6<269:BEOTWA>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
INFLAMMATORY BOWEL-DISEASE; EXPERIMENTAL ENDOTOXEMIA; PLASMINOGEN-ACTIVATOR; VASCULAR ENDOTHELIUM; VONWILLEBRAND-FACTOR; ULCERATIVE-COLITIS; INTERLEUKIN-6; CHIMPANZEES; INHIBITOR; CHILDREN;
Keywords:
CROHNS DISEASE; BLOOD COAGULATION; FIBRINOLYSIS; TUMOR NECROSIS FACTOR; CYTOKINES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
D.W. Hommes et al., "BENEFICIAL EFFECT OF TREATMENT WITH A MONOCLONAL ANTITUMOR NECROSIS FACTOR-ALPHA ANTIBODY ON MARKERS OF COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH ACTIVE CROHNS-DISEASE", Haemostasis, 27(6), 1997, pp. 269-277

Abstract

Crohn's disease has frequently been associated with coagulation abnormalities, causing intravascular deposition of fibrin and local infarction which can subsequently compromise the gut mucosa. Also, arterial and venous thromboembolic complications of larger vessels appear to be associated with Crohn's disease. Coagulation activation in patients with Crohn's disease could be a result of increased serum and tissue levels of cytokines, as reported. We prospectively studied parameters of coagulation and fibrinolysis in 10 patients with active Crohn's disease, who were subsequently treated with a monoclonal anti-tumor necrosisfactor-a (TNF) antibody. Ten consecutive patients with active Crohn'sdisease (CDAI > 150), not responding to a daily dose of at least 20 mg prednisolone, received a single infusion of human/mouse chimeric anti-TNF antibody cA2. All evaluable patients attained complete clinical and endoscopic remission within 4 weeks. Pretreatment plasma concentrations of markers of thrombin generation, thrombin-antithrombin (TAT) complexes and F1 + 2, were increased (22.1 +/- 11.8 mu g/l and 3.46 +/-1.2 nmol/l, respectively). After treatment with cA2, these levels almost completely normalized within 2 weeks. D dimer plasma levels were increased at baseline (377 +/- 61.3 mu g/l) and decreased to normal levels after cA2 treatment. The levels of plasminogen activator inhibitor(PAI-1) were elevated before treatment and slowly decreased hereafter. The levels of tissue-type plasminogen activator (t-PA) remained unchanged. Von Willebrand factor (vWf) levels were increased at baseline (159 +/- 21%) and showed a downward trend after 2 weeks (121.3 +/- 24%,NS). In conclusion, anti-TNF antibody infusion resulted in a decreaseof thrombin generation and endothelium activation markers in patientsthat were suffering from steroid-refractory Crohn's disease. These findings support the notion that active Crohn's disease is associated with the activation of coagulation and may indicate that this coagulation activation is mediated by TNF.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/09/20 alle ore 08:23:14